Sorrento Therapeutics Inc (SRNE)

[dia76ca]

There is a lot of news due in coming days, weeks and months!
We will receive the phase 3 SP-102 data in January. This should lead to SP-102 marketing in 2H of 2022. Sciatica and lower back pain are multi-billion dollar markets! The marketing teams are already being hired.

We should also expect news soon about Abivertinib marketing approval for NSCLC in China and a NDA application in the US. Abivertinb use against cytokine storm could also earn an EUA in Brazil, Mexico and the US at any time.

And worldwide marketing partners for COVISTIX and Abivertinib in cancer and cytokine storm could be announced soon. These worldwide partnerships could also be extended to COVI-AMG, COVIDROPS and COVI-MSC once they achieve EUA status. These are all in phase 2 status and interim analysis can be expected both for safety and efficacy. Many EUA's have been granted at this stage. Brazil, Mexico the UK , Europe and the US should all be interested.